Publications

1. Package advice tisagenlecleucel (Kymriah®) for the treatment of r/r DLBCL

   The National Health Care Institute has completed its reassessment whether tisagenlecleucel (Kymriah®) can be included in the ...

   Report | 25-01-2022

2. Package advice tucatinib (Tukysa®)

   The National Health Care Institute has completed its assessment whether tucatinib (Tukysa®) in combination with trastuzumab and ...

   Report | 17-01-2022

3. Package advice acalabrutinib (Calquence®) for the treatment of chronic lymphatic leukaemia

   The National Health Care Institute has completed its assessment whether acalabrutinib (Calquence®) can be included in the insured ...

   Report | 17-01-2022

4. GVS advice on volanesorsen (Waylivra)

   The National Health Care Institute advises the Minister to include volanesorsen on List 1B of the GVS. Volanesorsen (Waylivra®) ...

   Report | 10-01-2022

5. GVS advice Tezacaftor/ivacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) extension of further conditions

   The National Health Care Institute completed its assessment whether the further conditions of tezacaftor/ivacaftor (Symkevi®) and ...

   Report | 21-12-2021

6. Package advice on ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®) for the treatment of inoperable malign pleural mesothelioma

   The National Health Care Insititute has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab ...

   Report | 17-12-2021

7. Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS

   The National Health Care Institute has completed its assessment whether ravulizumab (Ultomiris®) can be included in the insured ...

   Report | 15-12-2021

8. GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis

   The National Health Care Institute recommends the Minister to include tirbanibulin on List 1A in cluster 0D06BBADC V of the GVS. ...

   Report | 01-12-2021

9. GVS advice fostemsavir (Rukobia®) for the treatment of adults with multidrug resistant HIV-1 infection

   The National Health Care Institute recommends the Minister to include fostemsavir (Rukobia®) in the GVS on List 1B and List 2 of ...

   Report | 01-12-2021

10. Package advice for the lock procedure drug osimertinib (Tagrisso®)

    The National Health Care Institute has completed its assessment whether osimertinib (Tagrisso®) can be included in the insured ...

    Report | 15-11-2021